GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.66
+9.45%Oct 1, 2026, 16:44 UTC
Monte Rosa Therapeutics reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102 and outlined plans to advance the treatment into multiple Phase 2 studies.
Source:Aug 6, 2026, 00:00 UTC
Monte Rosa Therapeutics reported its Q2 2026 financial results, with collaboration revenue of $9.0 million, a net loss of $43.4 million, and cash and investments of $626.0 million as of June 30, 2026.
Source: